EMA Application withdrawn: Vijoice (alpelisib) — Novartis Europharm Limited

View source ↗

Summary

The EMA has withdrawn the application for Vijoice (alpelisib) from Novartis Europharm Limited for genetic diseases and growth disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Diseases Inborn
• Growth Disorders

Drugs mentioned

• VIJOICE (ALPELISIB)

Snippet

Status: Application withdrawn. Therapeutic area: Genetic Diseases, Inborn;Growth Disorders. MAH: Novartis Europharm Limited. Orphan medicine